Diabetes Care, Vol 21, Issue 11 1803-1806, Copyright © 1998 by American Diabetes Association
Gestational diabetes: do lean young caucasian women need to be tested?
RG Moses, J Moses and WS Davis
Illawarra Area Health Service, Wollongong, New South Wales, Australia. robertvmoses@uow.edu.au
OBJECTIVE: The American Diabetes Association has recommended that pregnant
women with low-risk factors need not be tested for gestational diabetes
mellitus (GDM). The aim of this study was to determine the prevalence of
GDM in women with low-risk factors and to see if the pregnancy outcomes of
women with GDM from a low-risk group were different from the outcomes of
other women with GDM. RESEARCH DESION AND METHODS: Over an 18-month period,
all pregnant women were offered a test for GDM using a 75-g glucose
tolerance test at the beginning of the 3rd trimester. GDM was diagnosed if
the 2-h glucose level was > or =8.0 mmol/l. The prevalence of GDM was
determined in women with defined low-risk factors (Caucasian ethnic origin,
age <25 years, and BMI <25 kg/m2). The pregnancy outcomes of women
with GDM from a low-risk group were compared with those of other women with
GDM. RESULTS: From a tested population of 2,907 women, 573 were identified
as coming from a low-risk group. The prevalence of GDM in this low-risk
group was 2.8%. The pregnancy outcomes of women with GDM from a low-risk
group were no different from the pregnancy outcomes of other women with
GDM, with respect to frequency of insulin use, units of insulin per day,
morbidity, emergency caesarian section, and the percentage of both large-
and small-for-gestational-age babies. In our population, if low-risk women
were excluded, 80% of women would still require testing and nearly 10% of
all cases of GDM would be missed. CONCLUSIONS: Women from a low-risk group
have a 2.8% prevalence rate of GDM. The pregnancy outcomes of women with
GDM from a low-risk group are similar to the outcomes of other women with
GDM. Concerning the use of the 75-g glucose tolerance test in pregnancy,
the recommendation not to test women from a low-risk group requires further
evaluation in different populations before it can be endorsed.